1.1Macrocyclic chelation of gallium
A pendant linker attaches the macrocycle to the targeting ligand. The ring nitrogens and carboxylate oxygens coordinate gallium-68 when the conjugate contacts the radionuclide in a mildly acidic solution.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A pendant linker attaches the macrocycle to the targeting ligand. The ring nitrogens and carboxylate oxygens coordinate gallium-68 when the conjugate contacts the radionuclide in a mildly acidic solution.
A linker couples the chelator to a surface amine on the protein. Three hydroxamate groups coordinate zirconium-89 near neutral pH, and size-exclusion chromatography separates the labeled protein from unbound radionuclide.
Succinic acid and its sodium salts form a buffer at pH 5.5. The succinate species take up or release protons when the acidic radiometal solution enters the vial.
A cation-exchange cartridge captures the radiometal, and a wash removes the acidic carrier solution. A small volume of eluent transfers the radiometal to the 0.10 M acetate reaction mixture, where the lower acid load allows the buffer to hold pH 5.0.
Acetic acid and sodium acetate set the final reaction mixture to pH 4.0. This acidity suppresses gallium hydrolysis during chelation, and radiochromatography measures the resulting bound fraction.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An APD compound or salt in 0.5–1 M acetate buffer at pH 4.5–6.5 serves as the labeling mixture for a packed column flow experiment. The labeled product enters the liquid feed as a short pulse through a sample injection valve upstream of the column. An outlet fraction collector and a shielded radiation counter measure activity in successive fractions to generate a breakthrough curve for the labeled compound.
A succinic acid and sodium succinate buffer at pH 5.5 replaces the acetate buffer. The APD compound or salt dissolves in the succinate buffer, and an aliquot of metal radioisotope solution enters the buffered mixture under stirring. Radiochromatography separates the labeled APD fraction from unbound radiometal and measures the fraction of recovered activity in each.
A 250 µL conical reaction vial holds 40 µL of APD solution in 0.75 M acetate buffer at pH 5.5. A low-dead-volume syringe adds 10 µL of metal radioisotope solution, giving a 50 µL reaction volume and a final acetate concentration of 0.60 M. A heated block holds the vial at 60 °C for 15 minutes, and a companion mixture with the same reagent volumes serves to check the post-mixing pH.
A shielded synthesis module connects an APD acetate reaction vial to an anion exchange cartridge and a product collection vial through a switching valve. The module dilutes the reaction mixture with water before loading the cartridge to reduce the acetate concentration. The cartridge separates an anionic radiolabeled APD product from cationic radiometal, and a salt solution elutes the retained product into the collection vial. A radiochromatogram measures the radiochemical purity of the collected fraction.
A stirred reaction vial contains the APD compound or salt in acetate buffer and accepts a micro-pH electrode through its cap. After the metal radioisotope solution enters the vial, a controller reads the electrode and drives separate syringe pumps that deliver acetic acid or sodium acetate in small increments. The controller pauses after each addition for mixing and starts the heating cycle when the measured pH settles between 5.3 and 5.7. The run record stores the pH readings and the total volume dispensed by each pump.
A heated block holds three sealed vials containing the same APD compound or salt, acetate buffer, and metal radioisotope solution. A robotic sampler withdraws aliquots from separate vials at 5, 10, and 15 minutes and transfers them to a liquid chromatograph with a radiation detector. Software integrates the activity in the labeled APD peak and divides it by total recovered chromatographic activity. It records the earliest time that meets the preset radiochemical purity threshold for that reagent combination.
The vial contains the APD compound as a sodium salt. On dissolution, the salt dissociates and the buffer sets the protonation state of the APD species.
Acetic acid and sodium acetate give a combined acetate concentration of 0.50 M in the final mixture. Their ratio sets the final pH to 5.0 after addition of the radionuclide solution.
Acetic acid and sodium acetate give a combined acetate concentration of 1.00 M in the final mixture. The sodium acetate fraction is set to give a final pH of 5.8 after addition of the radionuclide solution.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The kit as described herein can not only provide an optimum pH for carrying out the chelation reaction or radiolabelling, but also allows to tolerate or manage the variation of the eluate volume and acidity associated with different types of gallium-68 generators, through the use of a suitable amount of acetate salt that when mixed with the acid generator eluate, form an acetic acid/acetate buffer having an acid pH comprised in the interval 3-5.A · US 11,027,030 B2 · ¶ 93
18F radioactive labeling: 740 MBq of 18F ions were mixed with 24 nmol AlCl3 in 100 μL of sodium acetate buffer (0.1 M, pH=4.0) and reacted for 5 min at room temperature.B · US 2024/0408248 A1 · ¶ 70
An empty cell means only that no passage was reproduced there.
However, due to the short half-life of gallium-68 (68 minutes), the radiotracer, i.e. radiolabelled chelate-functionalized targeting agent, based on this radioisotope are not suitable for long-distance distribution and require on the spot production and suitable production equipment, such as automated synthesizers, for the radiolabelling process, making it difficult for widespread use in routine nuclear medicine.A · US 11,027,030 B2 · ¶ 3
These additional steps however represent a loss of radioactivity resulting from, either wasted time or the process itself.A · US 11,027,030 B2 · ¶ 14
The development of specific nuclear medicine imaging drugs targeting Granzyme B can also play an important role in the imaging diagnosis, treatment monitoring, and efficacy evaluation of such diseases.B · US 2024/0408248 A1 · ¶ 6
The Granzyme B specific radiopharmaceutical of the present invention is easy to prepare and has good pharmacokinetic characteristics in vivo.B · US 2024/0408248 A1 · ¶ 7
patent.fyi, US 2026/0355362 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355362/, SHA-256 234d8b8a2aa546fc5541820dc412e784a3d65a0ac380df37f494f7969ecf6764